Aethl Bio adds limb salvage experts as advisors

Aethl Bio has named Dr. David Armstrong and Dr. Charles Zelen as advisors as the Pittsburgh biomaterials company advances its first wound dressing toward a planned FDA 510(k) filing. The move adds diabetic foot ulcer and wound care expertise to a product program that is still in development and not cleared for sale.

Why it matters: - Aethl Bio is trying to build clinical credibility around its wound care pipeline as it prepares a planned 510(k) premarket notification for its first dressing. - Dr. David Armstrong and Dr. Charles Zelen bring deep experience in diabetic foot ulcers, limb salvage and wound biologics research. - Stronger clinical strategy and evidence generation could help shape how the company positions Nuvoxen and future wound care products.

What happened: - Aethl Bio announced that Dr. Armstrong and Dr. Zelen have joined the company as advisors. - The appointments are meant to support clinical strategy, treatment application, research protocols and evidence generation for Nuvoxen. - The announcement came as Aethl Bio moves its first wound dressing toward a planned 510(k) premarket notification with the U.S. Food and Drug Administration. - Aethl Bio is based in Pittsburgh.

The details: - Dr. Armstrong is Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC. - Dr. Armstrong has authored more than 790 peer-reviewed papers. - Dr. Armstrong is Founding President of the American Limb Preservation Society. - Dr. Armstrong is the youngest recipient of the American Diabetes Association’s Roger Pecoraro Award and also received the Karel Bakker Award. - Dr. Armstrong said he will help guide clinical strategy and research protocols to support more ulcer-free, hospital-free and activity-rich days for people living with diabetic foot disease. - Dr. Zelen is founder and president of the Professional Education and Research Institute in Roanoke, Virginia. - Dr. Zelen is Podiatry Section Chief in the Department of Orthopedics at HCA LewisGale Medical Center. - Dr. Zelen is board-certified in foot surgery, reconstructive rearfoot and ankle surgery by the American Board of Foot and Ankle Surgery, and in podiatric medicine by the American Board of Podiatric Medicine. - Dr. Zelen performed some of the first randomized trials on amniotic membrane grafts in diabetic foot ulcers. - Dr. Zelen has led and co-authored many of the top multi-center trials of advanced wound biologics. - Dr. Zelen said he will help ensure the company’s research answers the questions clinicians and patients actually have. - Aethl Bio’s wound dressing is still in development, has not been cleared by the FDA and is not available for sale. - The company said academic and institutional affiliations are listed for identification only and do not imply endorsement, support, sponsorship or affiliation with Aethl Bio or its products. - Aethl Bio says it is developing advanced platforms for wound care and wellness applications on its proprietary Hydro-Activated Supersaturation platform. - Aethl Bio says its portfolio spans skin health, recovery and wellness. - The company says its mission is to help people heal deeply and live fully. - Aethl Bio says it can be found at Learn more. - The release also listed Aethl Bio’s LinkedIn, Facebook and X accounts: LinkedIn, Facebook and X.

Between the lines: - The advisor additions suggest Aethl Bio is leaning on established wound care researchers to strengthen the evidence base behind a still-unapproved product. - The emphasis on research protocols and evidence generation points to a strategy centered on clinician trust and regulatory readiness rather than marketing. - The company is pairing product development with external scientific credibility at a time when wound care remains crowded.

What's next: - Aethl Bio is expected to continue advancing its first wound dressing toward the planned FDA 510(k) filing. - The company’s advisory team may help shape study design and clinical positioning as development continues. - Any commercial launch would still depend on regulatory clearance before the wound dressing can reach the market.